TY - JOUR
T1 - Basal growth hormone concentrations in blood and the risk for prostate cancer
T2 - A case-control study
AU - Fuhrman, Barbara
AU - Barba, Maddalena
AU - Schünemann, Holger J.
AU - Hurd, Thelma
AU - Quattrin, Teresa
AU - Cartagena, Ruben
AU - Carruba, Giuseppe
AU - Muti, Paola
PY - 2005/7/1
Y1 - 2005/7/1
N2 - OBJECTIVE. To assess the relationship between basal serum growth hormone (GH) levels and prostate cancer risk. METHODS. We conducted a population-based case-control study; cases included 68 men, aged 45-85 years, diagnosed with incident, primary, histologically confirmed, and clinically apparent (stage B and higher) prostate cancer. Controls included 240 men, frequency matched on age and residential area. Age, race, BMI, waist circumference, history of enlarged prostate, education, and current smoking status, were all considered as possible confounders. RESULTS. We found a statistically significant trend of decreasing prostate cancer risk across increasing GH quintiles, in both crude (OR: 0.31, 95% CI: 0.12-0.83, P for trend 0.01) and adjusted models (OR: 0.35, 95% CI: 0.12-1.05, P for trend 0.03), in the highest compared to the lowest quintile, respectively. CONCLUSIONS. Lower basal levels of GH in serum are associated with increased prostate cancer risk. The inverse association may be explained by the negative feedback loop generated by IGF-1 produced by the tumor on GH secretion.
AB - OBJECTIVE. To assess the relationship between basal serum growth hormone (GH) levels and prostate cancer risk. METHODS. We conducted a population-based case-control study; cases included 68 men, aged 45-85 years, diagnosed with incident, primary, histologically confirmed, and clinically apparent (stage B and higher) prostate cancer. Controls included 240 men, frequency matched on age and residential area. Age, race, BMI, waist circumference, history of enlarged prostate, education, and current smoking status, were all considered as possible confounders. RESULTS. We found a statistically significant trend of decreasing prostate cancer risk across increasing GH quintiles, in both crude (OR: 0.31, 95% CI: 0.12-0.83, P for trend 0.01) and adjusted models (OR: 0.35, 95% CI: 0.12-1.05, P for trend 0.03), in the highest compared to the lowest quintile, respectively. CONCLUSIONS. Lower basal levels of GH in serum are associated with increased prostate cancer risk. The inverse association may be explained by the negative feedback loop generated by IGF-1 produced by the tumor on GH secretion.
KW - Epidemiological studies
KW - Growth hormone
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=20344380164&partnerID=8YFLogxK
U2 - 10.1002/pros.20203
DO - 10.1002/pros.20203
M3 - Article
C2 - 15666390
AN - SCOPUS:20344380164
SN - 0270-4137
VL - 64
SP - 109
EP - 115
JO - Prostate
JF - Prostate
IS - 2
ER -